Back to News
Market Impact: 0.4
Moderna Stock Plunges 18% As Leaked Melanoma Vaccine Data Underperforms
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Moderna shares recorded their steepest decline since August after leaked late-stage trial results for its personalized melanoma vaccine showed a smaller risk reduction than an earlier study. The article gives no percentage risk reduction or share-price decline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.40
Ticker Sentiment
MRNA-0.65
More News
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- Moderna shares plunge after leak of partial cancer vaccine data
- Moderna's stock tumbles after reported leak of data for cancer vaccine
- Moderna Stock Sinks Nearly 20% After Leak of Cancer-Vaccine Data
- Why Moderna stock plunged despite positive cancer vaccine trail results?
- Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports